Cargando…
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatien...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233643/ https://www.ncbi.nlm.nih.gov/pubmed/34173876 http://dx.doi.org/10.1186/s13561-021-00322-2 |
_version_ | 1783713899295539200 |
---|---|
author | Cicin, Irfan Oksuz, Ergun Karadurmus, Nuri Malhan, Simten Gumus, Mahmut Yilmaz, Ulku Cansever, Levent Cinarka, Halit Cetinkaya, Erdogan Kiyik, Murat Ozet, Ahmet |
author_facet | Cicin, Irfan Oksuz, Ergun Karadurmus, Nuri Malhan, Simten Gumus, Mahmut Yilmaz, Ulku Cansever, Levent Cinarka, Halit Cetinkaya, Erdogan Kiyik, Murat Ozet, Ahmet |
author_sort | Cicin, Irfan |
collection | PubMed |
description | BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. RESULTS: Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. CONCLUSIONS: Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00322-2. |
format | Online Article Text |
id | pubmed-8233643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-82336432021-06-28 Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective Cicin, Irfan Oksuz, Ergun Karadurmus, Nuri Malhan, Simten Gumus, Mahmut Yilmaz, Ulku Cansever, Levent Cinarka, Halit Cetinkaya, Erdogan Kiyik, Murat Ozet, Ahmet Health Econ Rev Research BACKGROUND: This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. METHODS: In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. RESULTS: Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. CONCLUSIONS: Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-021-00322-2. Springer Berlin Heidelberg 2021-06-26 /pmc/articles/PMC8233643/ /pubmed/34173876 http://dx.doi.org/10.1186/s13561-021-00322-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cicin, Irfan Oksuz, Ergun Karadurmus, Nuri Malhan, Simten Gumus, Mahmut Yilmaz, Ulku Cansever, Levent Cinarka, Halit Cetinkaya, Erdogan Kiyik, Murat Ozet, Ahmet Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title | Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title_full | Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title_fullStr | Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title_full_unstemmed | Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title_short | Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective |
title_sort | economic burden of lung cancer in turkey: a cost of illness study from payer perspective |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233643/ https://www.ncbi.nlm.nih.gov/pubmed/34173876 http://dx.doi.org/10.1186/s13561-021-00322-2 |
work_keys_str_mv | AT cicinirfan economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT oksuzergun economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT karadurmusnuri economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT malhansimten economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT gumusmahmut economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT yilmazulku economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT canseverlevent economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT cinarkahalit economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT cetinkayaerdogan economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT kiyikmurat economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT ozetahmet economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective AT economicburdenoflungcancerinturkeyacostofillnessstudyfrompayerperspective |